Who should avoid this treatment
Many women report reduced anxiety and improved mood after starting treatment, partly from the weight loss itself and partly from the direct neurological effects of GLP-1 receptor activation on mood-regulating brain circuits
Additionally, a deficiency of vitamin D has been associated with worse adverse effects during oncologic treatments (69, 70)
Unlike many experimental NRF2 activators (e.g., synthetic electrophiles or natural compounds like sulforaphane), DMF has undergone extensive Phase III trials, demonstrating its efficacy and safety in humans
This could translate to better adherence, improved glycemic control, and greater patient satisfaction
Follow-up screening during the first year helps us detect changes when they are earliest and most responsive to treatment